George Peoples - Sep 20, 2024 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role
Director
Signature
/s/ Andrew Jackson, Attorney-in-fact
Stock symbol
CLDI
Transactions as of
Sep 20, 2024
Transactions value $
$0
Form type
4
Date filed
10/15/2024, 09:14 PM
Previous filing
Jul 11, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDI Non-Qualified Stock Options (right to buy) Award +20.2K 20.2K Sep 20, 2024 Common stock 20.2K $1.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the "Options") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the "Grant Date"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date.

Remarks:

Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 3 dated July 8, 2024).